VERAXA Biotech clears final shareholder hurdle as Voyager Acquisition votes yes on $1.35bn oncology de-SPAC

Voyager Acquisition Corporation (NASDAQ: VACH), a special purpose acquisition company sponsored by Cantor Fitzgerald and Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC, received shareholder approval at its general meeting on March 12, 2026 for the previously announced business combination with VERAXA Biotech AG, a Zurich-headquartered oncology platform company developing next-generation antibody-drug conjugates and bispecific T-cell engagers. The vote clears what was the last outstanding shareholder condition required to proceed to closing, with the combined entity expected to begin trading on NASDAQ under the ticker symbol VRXA shortly after customary listing approval. VERAXA Biotech AG shareholders had already voted in favour of the underlying merger structure at an extraordinary general meeting on February 27, 2026, making the Voyager vote the decisive gateway event. The transaction, originally announced in April 2025 and structured as a de-SPAC combination, values VERAXA at a pre-money equity value of approximately $1.35 billion.

What does the Voyager Acquisition and VERAXA Biotech combination mean for investors pursuing NASDAQ oncology listings in 2026?

The shareholder vote resolves one of the few remaining procedural barriers to VERAXA Biotech AG accessing U.S. public capital markets, a path the company has been building toward since striking the definitive agreement with Voyager Acquisition Corporation in April 2025. The structural mechanics of the transaction involve an absorption merger in which Veraxa Biotech Holding AG, as the acquiring entity, takes over VERAXA Biotech AG as the transferring company and simultaneously renames itself Veraxa Biotech AG. This holding company layer is the vehicle through which Voyager’s remaining public shareholders will receive shares in the combined company, with the existing management team led by Chief Executive Officer Christoph Antz continuing to operate the business without interruption.

The transaction is structured to give VERAXA Biotech AG access to cash held in Voyager Acquisition Corporation’s trust account, originally up to $253 million assuming no shareholder redemptions. The redemption outcome, however, tells a very different story about SPAC market dynamics in 2026. Holders of 25,217,315 Class A ordinary shares elected to redeem, representing approximately 99.67% of the total Class A shares outstanding. The practical consequence is that approximately $885,556 will remain in Voyager Acquisition Corporation’s trust account following redemptions, with only 82,685 Class A shares converting into shares of Veraxa Biotech Holding AG. The gap between the original $253 million trust and the sub-million-dollar residual is substantial, and it places VERAXA’s near-term operating and clinical runway squarely in the hands of the crossover financing round and any strategic partnerships the company secures around the time of listing.

Why have almost all Voyager Acquisition shareholders chosen to redeem rather than roll into VERAXA Biotech Holding AG?

A near-total redemption rate is not unusual in the current de-SPAC environment, where institutional SPAC arbitrage strategies routinely result in the majority of trust capital exiting before a combination closes. Investors who purchased VACH units at or near the $10 IPO price in August 2024 had a structurally protected exit option, and in the absence of a compelling reason to maintain exposure to a pre-revenue oncology platform, most chose to exercise it. This behaviour is consistent with what the broader SPAC market has produced since 2022, when high redemptions became the norm rather than the exception for healthcare and technology de-SPAC transactions.

For VERAXA Biotech AG, the commercial implication is that the path to NASDAQ is intact but the expected cash infusion from Voyager Acquisition Corporation’s trust is now negligible. The company must therefore rely on the crossover financing round it began structuring ahead of the combination, as well as the strategic licensing and partnership opportunities it has been actively pursuing through 2025 and into 2026. The VERAXA pipeline is capital-intensive by design, with nine development programs including the Phase 1 candidate VX-A901 in leukemia and a broader slate of preclinical work targeting solid tumors. Advancing those programs through clinical inflection points will require a financing strategy that goes substantially beyond what the Voyager trust now provides.

How does VERAXA Biotech’s BiTAC platform differentiate its ADC and T-cell engager pipeline from established oncology competitors?

VERAXA Biotech AG was founded on research originating at the European Molecular Biology Laboratory, and the company’s central technology is the proprietary Bi-Targeted Antibody Cytotoxicity, or BiTAC, platform. The platform enables a dual-marker approach in which antibody-based therapies target two distinct surface antigens simultaneously, a design intended to improve specificity against tumor cells while limiting off-target toxicity. The two primary therapeutic modalities being advanced are BiTAC antibody-drug conjugates, referred to internally as BiTAC ADCs and bsADCs, and bispecific antibodies designed to engage T-cells, referred to as BiTAC TCEs. Both categories sit within the fastest-growing segments of the oncology drug development landscape.

Market projections for these modalities reflect their strategic appeal to investors and pharma partners. The bispecific T-cell engager market is estimated to reach $112 billion by 2030, representing a compound annual growth rate exceeding 44%, while the antibody-drug conjugate market is projected to reach $57 billion by 2030 at a compound annual growth rate of approximately 30%. These figures contextualise why a Zurich-based biotech founded on academic science would choose a NASDAQ listing as its capital-raising vehicle. European small-cap oncology companies have struggled to attract the analyst coverage and institutional flow needed to sustain clinical-stage valuations on domestic exchanges, making a U.S. listing strategically logical despite the structural hazards of the de-SPAC route.

The competitive landscape VERAXA is entering is formidable. Large pharmaceutical companies including AstraZeneca, Daiichi Sankyo, and Pfizer have made substantial bets on ADC technology, acquiring or partnering with ADC specialists at valuations that reflect the category’s commercial maturity. VERAXA’s differentiation argument rests on the bispecific architecture of its platform, which it positions as capable of delivering safety and efficacy improvements over conventional ADCs. Whether that differentiation is meaningful at the clinical level will only become clear as VX-A901 and subsequent programs generate data, and the company will be presenting those data sets to investors and potential partners from a newly listed public platform.

What strategic partnerships and licensing deals is VERAXA Biotech AG pursuing as it approaches its NASDAQ listing under ticker VRXA?

VERAXA Biotech AG has not been waiting passively for the SPAC transaction to close before building out its external relationships. The company entered a co-discovery alliance with OmniAb for a novel bispecific antibody drug conjugate program in May 2025, and separately established a partnership with Secarna Pharmaceuticals that combines Secarna’s OligoCreator oligonucleotide platform with VERAXA’s antibody technology suite, targeting autoimmune and inflammatory diseases as a secondary indication category beyond oncology. These moves signal a strategy of building partnership density ahead of listing, which reduces the single-product risk profile that typically weighs on pre-revenue biotechs in public markets and creates potential near-term licensing revenue streams.

The Cantor Fitzgerald relationship embedded in the Voyager Acquisition Corporation sponsorship structure is also notable in a commercial context. Cantor Fitzgerald serves as capital markets adviser for the transaction and appeared alongside VERAXA representatives at major industry conferences including the ASCO Annual Meeting and the BIO International Convention in mid-2025. That institutional channel matters for a company at VERAXA’s stage because sell-side analyst initiation, investor roadshows, and early institutional positioning are all functions that a banking sponsor with oncology coverage capability can accelerate. Whether that translates into meaningful post-listing trading liquidity for VRXA shares will be one of the near-term measures of whether the de-SPAC route delivered on its commercial rationale for VERAXA.

How does the VACH stock performance and redemption outcome reflect broader SPAC market conditions for healthcare listings in 2026?

Voyager Acquisition Corporation’s Class A ordinary shares have traded in a narrow range consistent with trust value, with the 52-week range running from $9.95 to $11.20 and the stock sitting near $11 as of March 12, 2026. This price behaviour is entirely typical of a SPAC in the final stages of a business combination, where the downside protection of the trust floor and the redemption option compress price discovery to a narrow corridor around intrinsic trust value. The near-total redemption rate of 99.67% is itself a market signal worth interpreting: SPAC investors at this stage are functioning as structured arbitrageurs rather than equity investors in the target company, and their exit via redemption reflects rational capital allocation rather than a negative view of VERAXA’s pipeline specifically.

The more analytically relevant market signal will emerge once VRXA begins trading as a standalone oncology stock. At that point, the pro forma equity value of approximately $1.64 billion will face the scrutiny of the broader biotech investor community, and the absence of material trust cash will force a cleaner assessment of the company’s intrinsic value based on the pipeline, the BiTAC platform, and the crossover financing terms. Healthcare SPAC combinations with high redemption rates have historically traded at a discount to their deal equity valuations in the weeks following listing, as index-ineligibility and low float constrain institutional participation. VERAXA Biotech AG and its new shareholders will be navigating that post-listing period while simultaneously managing clinical execution and partnership development.

What execution risks and capital structure challenges does VERAXA face as it transitions from private biotech to NASDAQ-listed public company?

The most immediate execution risk for VERAXA Biotech AG is financing. With the Voyager Acquisition Corporation trust account reduced to approximately $885,556 by redemptions, the company’s working capital and clinical development budget will be determined by how successfully it has closed the crossover round it began pursuing ahead of the combination, and by the terms of any near-term licensing transactions. Clinical-stage oncology companies with nine development programs and a Phase 1 asset in active trials have substantive burn rates, and the BiTAC platform’s breadth is an asset in a partnering context but a cash consumption challenge if development is pursued primarily in-house. VERAXA’s management will need to be disciplined about pipeline prioritisation in the immediate post-listing period.

The Swiss domicile of the operating company adds a layer of complexity. VERAXA Biotech AG operates from Zurich with research infrastructure at the Heidelberg facility, and the listing vehicle is structured through a Swiss holding entity. Foreign private issuers on U.S. exchanges operate under a different disclosure regime than domestic companies, and compliance costs for a dual-market presence, even without a formal European listing, are not trivial for a company of VERAXA’s size. The transaction structure also required an extraordinary capital increase of up to CHF 223,400 to facilitate the issuance of new shares to Voyager shareholders, a procedural step that was approved at the February 27, 2026 extraordinary general meeting but reflects the complexity of reconciling Swiss corporate law with U.S. securities requirements.

The Voyager Acquisition Corporation transaction deadline has been extended to August 7, 2026 through an amendment to the business combination agreement, providing a runway buffer if closing procedures encounter further delays. The same amendment raised the implied merger consideration to approximately $1.35 billion, removed the SPAC termination fee applicable in certain termination scenarios, and required the sponsor to surrender 200,000 founder shares and 400,000 private placement warrants at closing. The surrender of sponsor shares is a concession that modestly aligns sponsor economics with post-listing shareholder outcomes, though it does not materially alter the dilution arithmetic for incoming VRXA shareholders.

Key takeaways: What the VERAXA Biotech and Voyager Acquisition combination approval means for oncology investors, SPAC markets, and ADC sector competition

• Voyager Acquisition Corporation (NASDAQ: VACH) shareholders approved the business combination with VERAXA Biotech AG on March 12, 2026, clearing the final shareholder condition for the combined company to list on NASDAQ under the ticker VRXA.
• A 99.67% Class A share redemption rate leaves only approximately $885,556 in Voyager’s trust account, far below the originally projected $253 million, making the crossover financing round and licensing strategy the primary near-term capital events for VERAXA.
• The transaction values VERAXA Biotech AG at approximately $1.35 billion pre-money, with a pro forma equity value of approximately $1.64 billion for the combined entity, benchmarks that will be tested by post-listing trading in what is likely to be a thinly traded early float.
• VERAXA’s BiTAC platform targets two of the highest-growth oncology modalities: the ADC market projected at $57 billion by 2030 and the TCE market projected at $112 billion by 2030, with compound annual growth rates of approximately 30% and 44% respectively.
• The nine-program pipeline, including Phase 1 asset VX-A901 in leukemia, provides a basis for partnership discussions and licensing transactions, but also represents a capital consumption challenge in a post-listing environment where trust cash has been almost entirely redeemed.
• Strategic alliances with OmniAb and Secarna Pharmaceuticals, announced in 2025, show a deliberate pre-listing effort to build partnership optionality and reduce single-asset risk, a capital efficiency approach common among European oncology biotechs pursuing U.S. listings.
• Cantor Fitzgerald’s dual role as SPAC sponsor and capital markets adviser provides institutional distribution infrastructure for the post-listing investor relations effort, a structural advantage relative to de-SPAC transactions without a bulge-bracket banking relationship.
• Historical de-SPAC performance data suggests VRXA will face post-listing discount pressure due to low float, index-ineligibility in the near term, and high redemption overhang, creating potential entry points for longer-duration oncology investors willing to accept early-stage platform risk.
• The transaction deadline extension to August 7, 2026 provides closing buffer, but the sponsor concessions including surrender of 200,000 founder shares and 400,000 warrants reflect the negotiating realities of a high-redemption SPAC environment.
• VERAXA’s European EMBL scientific heritage and Swiss operating base represent both a differentiation argument in the ADC competitive landscape and a compliance overhead for a U.S.-listed foreign private issuer, a tension management will navigate in parallel with clinical development.